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Abstract
Aims/hypothesis In this study, we aimed to evaluate the
therapeutic potential of 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR), an activator of AMP-activated
protein kinase, for ameliorating high-fat diet (HFD)-induced
pathophysiology inmice.We also aimed to determine whether
the beneficial effects of AICAR were dependent on
adiponectin. Furthermore, human adipose tissue was used to
examine the effect of AICAR ex vivo.
Methods Six-week-old male C57BL/6J wild-type and
Adipoq−/− mice were fed a standard-fat diet (10% fat) or an
HFD (60% fat) for 12 weeks and given vehicle or AICAR
(500 μg/g) three times/week from weeks 4–12. Diet-induced
pathophysiology was examined in mice after 11 weeks by
IPGTT and after 12 weeks by flow cytometry and western
blotting. Human adipose tissue biopsies from obese (BMI
35–50 kg/m2) individuals were incubated with vehicle or
AICAR (1 mmol/l) for 6 h at 37°C, after which inflammation
was characterised by ELISA (TNF-α) and flow cytometry.
Results AICAR attenuated adipose inflammation in mice fed
an HFD, promoting an M1-to-M2 macrophage phenotype
switch, while reducing infiltration of CD8+ T cells. AICAR
treatment of mice fed an HFD partially restored glucose
tolerance and attenuated hepatic steatosis and kidney disease,
as evidenced by reduced albuminuria (p<0.05), urinary H2O2
(p < 0.05) and renal superoxide levels (p < 0.01) in both
wild-type and Adipoq−/− mice. AICAR-mediated protection
occurred independently of adiponectin, as similar protection
was observed in wild-type and Adipoq−/− mice. In addition,
AICAR promoted an M1-to-M2 macrophage phenotype
switch and reduced TNF-α production in tissue explants from
obese human patients.
Conclusions/interpretation AICAR may promote metabolic
health and protect against obesity-induced systemic diseases
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in an adiponectin-independent manner. Furthermore, AICAR
reduced inflammation in human adipose tissue explants,
suggesting by proof-of-principle that the drug may reduce
obesity-induced complications in humans.
Trial registration: ClinicalTrials.gov NCT02322073
Keywords Adiponectin . AICAR . Inflammation . Kidney
disease . Liver disease . Macrophages . Obesity
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Introduction
The obesity pandemic poses a serious public health challenge.
Obesity is associated with numerous pathologies, including
diabetes, non-alcoholic fatty liver disease and kidney disease
[1, 2]. There are currently more overweight than underweight
people worldwide [3]; this increase in prevalence has
prompted a search for effective treatments to tackle obesity-
related pathophysiology.
The adenosinemonophosphate analogue 5-aminoimidazole-
4-carboxamide ribonucleotide (AICAR) activates AMP-
dependent protein kinase (AMPK), which is a key regulator
of energy metabolism and thus a potential target for treatment
of obesity-related complications [4, 5]. Evidence from
experimental models has shown that AICAR may attenuate
metabolic [6–8], hepatic [9–11] and renal pathophysiology
[12–15]. However, the use of AICAR could be compromised
as some reports indicate that AICAR increases adiponectin
production [13]. Although adiponectin is generally described
as a protective adipokine [16], several clinical studies have
reported a paradoxical inverse association between circulating
adiponectin levels and renal function [17, 18]. Specifically,
increased adiponectin levels correlate with diabetic
nephropathy [19, 20], advanced chronic kidney disease
(CKD) [21–23] and increased risk of mortality [24]. As we
cannot exclude the compromising role of adiponectin in CKD
patient groups, it is critical to assess if AICAR-mediated actions
are adiponectin dependent to determine its suitability as a drug
to target obesity-related pathophysiology.
The aims of this study were to evaluate the therapeutic
potential of AICAR for the promotion of metabolic health
and reduction of liver and kidney disease in mice fed a
high-fat diet (HFD) and to determine if such protection was
dependent on adiponectin. Since white adipose tissue (WAT)
inflammation is a key driver of obesity-related pathophysiology
[25–29], this was characterised in detail. Finally, to translate our
rodent data to human pathophysiology, we also investigated
whether AICAR could reduce inflammation in omental WAT
tissue explants obtained from obese individuals undergoing
gastric bypass surgery.
Methods
Animal study Six-week-old male wild-type (C57BL/6J) and
Adipoq−/− (B6;129-Adipoqtm1Chan/J) mice (catalogue numbers
000664 and 008195, respectively; The Jackson Laboratory,
Sacramento, CA, USA) were housed in a temperature/
humidity controlled room on a 12 h light/12 h dark cycle.
Mice were allowed to acclimatise for a minimum of one week
prior to commencement of experiments, as described in the
electronic supplementary material (ESM) Methods. Mice
were fed a sucrose-matched standard-fat diet (SFD; 10% fat)
or an HFD (60% fat) for 12 weeks (n=3–17 per experiment,
as indicated in the respective figure legends). During weeks
4–12 of SFD/HFD feeding, vehicle or AICAR (500μg/g [13])
was given three times per week via i.p. injections. Mice were
randomly assigned in consecutive order to an SFD or HFD,
and to vehicle or AICAR treatment. At week 11, we
performed a fasted IPGTT [30] and collected urine for 24 h
to assess microalbuminuria and urine H2O2 levels. At the end
of the study, WAT and kidney leucocytes were isolated and
characterised by flow cytometry. AMPK activation in WAT
was determined by western blot analysis. Liver morphology
was visualised by haematoxylin and eosin staining and hepatic
free cholesterol and triacylglycerol concentrations were mea-
sured using standardised kits (cholesterol: WAKO,
Richmond, VA, USA; triacylglycerol: Pointe Scientific,
Canton, MI, USA). Plasma creatinine was measured by
HPLC. In a subset of mice, dihydroethidium (DHE, 50mg/kg)
was administered by i.p. injection 16 h before the mice were
killed to quantify renal superoxide levels by confocal imaging
(n=4 per group) [14]. Detailed protocols for liver function
analysis, HPLC plasma creatinine analysis and renal superox-
ide measurements are described in ESM Methods.
J774 experiments Serum-starved J774 macrophages were
treated with vehicle or AICAR (1 mmol/l) for 16 h [31].
Cellular p-AMPK/AMPK was quantified by western blot
analysis. Cells were characterised by flow cytometry as
proinflammatory M1 macrophages (CD11c+) or anti-
inflammatory M2 macrophages (CD206+); values from
vehicle-treated cells were set at 100%.
Human adipose explant culture Omental WAT explants
were obtained from obese (BMI 35–50 kg/m2) non-diabetic
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individuals (n=4) undergoing bariatric surgery. WATexplants
were incubated ex vivo (1 g tissue per 2 ml DMEM) with
vehicle or AICAR (1 mmol/l) for 6 h at 37°C (see ESM
Methods for further details). Supernatant TNF-α levels were
determined by ELISA and tissue leucocytes were
characterised by flow cytometry.
Leucocyte phenotyping by flow cytometry Tissue
leucocytes were isolated by treating WAT and kidneys with
collagenase (5 mg/ml and 10 mg/ml, respectively) at 37°C
[29, 32]. Lysates were filtered (70 μm pore size) and 5×105
cells were stained by Aqua-Live-Dead (Thermo Fisher,
Waltham, MA, USA) and relevant antibodies for characteri-
sation (see ESM Table 1 and ESM Table 2 for antibody de-
tails). Both human and murine lymphocytes (CD3+CD45+)
were characterised as T helper (% CD4+ of CD3+CD45+)
and cytotoxic T cells (% CD8+ of CD3+CD45+). In murine
tissues, F4/80+ macrophages (CD45+F480+) were
subcategorised as inflammatory M1 macrophages (%
CD11c+ of CD45+F480+) or M2 macrophages (% CD206+
of CD45+F480+). In human WAT, the mononuclear/
macrophage population (CD45+) was identified as M1 mac-
rophages (% CD11c+ of CD45+), M2a macrophages (%
CD206+ of CD45+), M1/M2b macrophages (% CD86+ of
CD45+) or M2a/M2c macrophages (% CD163+ of CD45+).
Gating was determined using Fluorescence-Minus-One con-
trols (see ESM Methods for further details).
Western blot analysisAdipose tissue and serum-starved J774
macrophages were homogenised in RIPA lysis buffer. Briefly,
40 μg protein was loaded onto a 16% SDS-PAGE gel and
transferred onto polyvinylidene difluoride (PVDF) membranes
(0.2 μm pore size) [31]. Proteins were identified using rabbit
anti-p-AMPKα (Thr172; no. 2535s), rabbit anti-AMPKα
(no. 2532s) and rabbit anti-adiponectin (no. 2789) antibodies
(all diluted 1:1000; Cell Signaling, Danvers, MA, USA).
Proteins were normalised against β-actin (mouse anti-β-actin
antibody [no. A2228]; Sigma, St Louis, MO, USA), diluted
1:10,000 (see ESM Methods for further details). Original
western blot images were cropped as indicated by vertical lines.
Study approval The Veterans Affairs San Diego Healthcare
System Institutional Animal Care and Use Committee
(IACUC) approved all animal procedures (approval no. 10-029),
and the Guide for the Care and Use of Laboratory Animals
was followed during experiments. Human tissue specimens
were obtained from a larger study (ClinicalTrials.gov
NCT02322073) in agreement with the principal investigator,
V. Wallenius. The Regional Ethical Review Board (Gothenburg,
Sweden) approved all study procedures (Dnr 682-14) and all pa-
tients were enrolled in accordance with the Helsinki Declaration.
Written informed consent was obtained from all participants
included in this study.
Statistical analyses Gaussian distribution was assumed and
two-tailed Student’s t test, or two-way ANOVA with paired
Bonferroni correction as a post hoc comparison was used, as
indicated in the figure legends. Analyses were performed
using GraphPad Prism version 5 (La Jolla, CA, USA),
licensed to UC San Diego.
Results
AICAR attenuated HFD-induced adipose inflammation
independent of adiponectin Wild-type and Adipoq−/− mice
were fed a sucrose-matched SFD (10% fat) or HFD (60% fat)
for 12 weeks (ESM Fig. 1a). Because this HFD regime has
previously been shown to cause systemic disease after
4 weeks, such as renal impairment [13], we initiated AICAR
treatment at week 4 to test the effect of AICAR as an
intervention.
As expected, HFD-fed mice gained significantly more
weight than mice fed an SFD (ESM Fig. 1b). AICAR is
known to increase metabolism and weight loss [7], even in
sedentary mice [8]. Accordingly, we observed that AICAR
attenuated weight gain during the final few weeks of the diet
regimen, both in wild-type and Adipoq-/- mice (ESM Fig. 1b).
However, AICAR-treated HFD-fed mice weighed significantly
more than controls fed an SFD in both mouse strains
throughout the study (ESM Fig.1b).
The total number of F4/80+ macrophages was not affected
by HFD in perigonadal WAT fromwild-type mice (Fig. 1a), in
accordancewith our previous studies [29]. However, HFD-fed
Adipoq−/−mice presented with an increased number of F4/80+
macrophages (p<0.05; Fig. 1a).Adipoq−/−mice fed either diet
exhibited a higher percentage of CD11c+ M1 macrophages
compared with their respective wild-type controls (p<0.001;
Fig. 1b).
AICAR attenuated HFD-induced WAT inflammation in
both mouse strains; in wild-type mice, AICAR treatment
reduced the percentage of CD11c+ M1 macrophages
(p<0.01) and increased levels of anti-inflammatory CD206+
M2 macrophages (p<0.001; Fig. 1b–d). Similarly, AICAR
attenuated HFD-induced CD11c+ M1 macrophages in
Adipoq−/− mice (p<0.001). Macrophage CD206+ expression
was increased in SFD-fed Adipoq−/− mice compared with
SFD-fed wild-type mice, but there were no changes between
Adipoq−/−mice on an SFD or an HFD with or without AICAR
treatment (Fig. 1c). AICAR also reduced the percentage of
cytotoxic CD8+ T cells in both mouse strains but did not affect
levels of CD4+ T cells (Fig. 1e–h). Although we and others
have previously shown that HFD reduces p-AMPK/AMPK
[13], surprisingly HFD did not alter AMPK activity in WAT
in the present study. This may be explained by the fact that we
matched sucrose levels in SFD and HFD regimens in the
present study. However, as expected, AICAR increased WAT
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p-AMPK/AMPK levels (Fig. 1i). Furthermore, AICAR did not
restore HFD-mediated attenuation of WAT adiponectin in
wild-type mice (Fig. 1j).
WAT comprises a myriad of cells, including adipocytes,
epithelial cells and leucocytes. To determine if AICAR could
alter the macrophage phenotype via direct or indirect effects,
we also investigated AICAR-mediated effects on murine
macrophages in vitro, using the J774 cell line. Similar to the
in vivo findings, AICAR promoted an M1-to-M2 phenotype
switch in culturedmacrophages, attenuatingCD11c++ expression
(p<0.01), while promoting CD206+ expression (p<0.05;
Fig. 2a,b). This correlated with increased p-AMPK/AMPK in
this cell line (p<0.05; Fig. 2c,d), but AMPK/β-actin remained
unaltered (Fig. 2c,e).
AICAR partially restored glucose tolerance in obese mice
independent of adiponectin An IPGTT was performed to
assess glucose tolerance (Fig. 3a–c). HFD significantly
impaired glucose clearance in both wild-type and Adipoq−/−
mice (p < 0.001). However, HFD-fed Adipoq− /−mice
presented with exaggerated glucose intolerance compared
with HFD wild-type controls (p<0.05) (Fig. 3c).
AICAR did not significantly alter the HFD-induced
increase in fasting blood glucose in either mouse strain
(Fig. 3a,b). However, AICAR partially restored HFD-
induced impairment of glucose clearance in wild-type mice
(p<0.05). This AICAR-mediated beneficial effect on glucose
clearance was sustained in the Adipoq−/− mice (p< 0.05;
Fig. 3c) and significantly lower levels of blood glucose were
observed in AICAR-treated vs untreated HFD Adipoq−/−at
60 min and 120 min post-glucose injection (Fig. 3b).
AICAR attenuated HFD-induced hepatic steatosis
independent of adiponectin AICAR reduced HFD-induced
hepatic steatosis, as evidenced by reduced hepatic
vacuolisation (Fig. 4a) and triacylglycerol content (Fig. 4b).
The drug also attenuated HFD-induced elevations in hepatic
cholesterol levels in Adipoq−/− mice (p < 0.05; Fig. 4c).
Furthermore, AICAR-mediated attenuation of hepatic
vacuolisation was more pronounced in Adipoq−/− mice
(Fig. 4a). Liver weight/hypertrophy was not altered by
AICAR treatment (ESM Fig. 2).
AICAR attenuated HFD-induced kidney disease independent
of adiponectin Wild-type and Adipoq−/− mice developed
significant renal dysfunction following a 3 month HFD
regimen, as evidenced by increased albuminuria, urine H2O2
and renal superoxide production compared with SFD
(Fig. 5a,b,d), without changes in plasma creatinine (ESM
Fig. 3). Furthermore, renal hypertrophy was increased in
HFD-fed Adipoq−/− mice compared with SFD (Fig. 5c). The
total number of renal F4/80+ pan-macrophages was not altered
byHFD in either mouse strain (Fig. 5e), but HFD significantly
Fig. 1 AICAR attenuates adipose inflammation independent of
adiponectin in obese mice. Wild-type and Adipoq−/− mice fed a
12 week SFD (10% fat) or HFD (60% fat) received vehicle or AICAR
(500 μg/g) during weeks 4–12. WAT leucocytes were characterised by
flow cytometry; (a)–(d) Macrophages were characterised as
pan-macrophages (F4/80+), proinflammatory M1-macrophages
(CD11c+) or anti-inflammatory M2-macrophages (CD206+) (n = 5).
(e)–(h) Lymphocytes were characterised as T killer (CD8+) vs T helper
(CD4+) cells (n= 5). (i), (j) AMPK activation and adiponectin levels were
analysed by western blot. AMPK blots were cut as indicated (full blots
and details of cutting are presented in ESM Fig. 4) (n = 3). Data are
presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001;
ANOVA with Bonferroni correction; †p< 0.05, ††p< 0.01, †††p < 0.001,










































































































Fig. 2 AICAR promotes AMPK
activation and an M1-to-M2
phenotype switch in cultured
macrophages. J774 macrophages
were incubated with vehicle or
AICAR (1 mmol/l) for 16 h
(n = 3). Cells were characterised
as (a) proinflammatory M1
(CD11c++) or (b) anti-
inflammatory M2 (CD206+) by
flow cytometry and (c–e)
p-AMPK/AMPKwas assessed by
western blot. Data are presented
as mean ± SEM. *p< 0.05,
**p< 0.01, paired Student’s t test
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increased renal CD11c+ M1 macrophages in wild-type mice
(Fig. 5f,g). Renal CD11c+ M1 macrophage levels were higher
in Adipoq−/−mice compared with wild-type mice fed an SFD,
but no additional increase was observed in HFD-fed Adipoq−/−
mice (Fig. 5f,h).
AICAR significantly attenuated HFD-induced albuminuria
(Fig. 5a), urinary H2O2 (Fig. 5b) and renal superoxide
(Fig. 5d) in both wild-type and Adipoq− /− mice.
Furthermore, AICAR attenuated HFD-induced renal
hypertrophy in Adipoq−/− mice (Fig. 5c). Finally, AICAR
completely attenuated the HFD-induced increase in renal
CD11c+ M1 macrophages in the wild-type strain (Fig. 5f).
AICAR reduced adipose inflammation in tissue explants
obtained from obese human patientsWAT inflammation is
a key driver of obesity-related pathophysiology [26–29]. As a
proof-of-principle for translating our rodent data to human
pathophysiology, we investigated whether AICAR could
reduce inflammation and manipulate leucocyte phenotypes
in omentalWATexplants taken from obese patients undergoing
gastric bypass surgery.
The antigens used to phenotype human macrophages
varied slightly from the panel used for mice. Thus, we
characterised human macrophages using the following
activation markers: CD11c+ (M1), CD86+ (M1/M2b),
a b


































































































Fig. 3 AICAR partially restores glucose tolerance independent of
adiponectin in obese mice. Wild-type and Adipoq−/− mice fed a 12 week
SFD (10% fat) or HFD (60% fat) received vehicle or AICAR (500 μg/g)
during weeks 4–12 of feeding. Glucose tolerance was tested at week 11
by an IPGTT in (a) wild-type (n = 4 for all groups) and (b) Adipoq−/−
(n = 3 for SFD and HFD, n = 7 for HFD+AICAR) mice. Circles, SFD;
squares, HFD; triangles, HFD+AICAR. (c) Graph of the AUC of IPGTT
curves. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01,
***p< 0.001, ANOVAwith Bonferroni correction; †p< 0.05, ††p < 0.01,
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Fig. 4 AICAR attenuates hepatic
steatosis independent of
adiponectin in obese mice. Wild-
type and Adipoq−/− mice fed a
12 week SFD (10% fat) or HFD
(60% fat) received vehicle or
AICAR (500 μg/g) during weeks
4–12. (a) Representative images
of hepatic haematoxylin and eosin
staining (magnification× 40).
Hepatic (b) triacylglycerol and (c)
cholesterol (n= 3). Data are
presented as mean ± SEM.
*p< 0.05, **p< 0.01, ANOVA
with Bonferroni correction
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CD206+ (M2a) or CD163+ (M2a/M2c). This classification is
based on the Martinez et al scheme, whereby M1
macrophages display potent inflammatory activities, whereas
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Fig. 5 AICAR attenuates kidney disease independent of adiponectin in
obese mice. Wild-type and Adipoq−/− mice fed a 12 week SFD (10% fat)
or HFD (60% fat) received vehicle or AICAR (500 μg/g) during weeks
4–12. (a) Micro-albuminuria, (b) urine H2O2 and (c) renal hypertrophy
were assessed (n= 7). (d) DHE was injected 16 h prior to killing the mice
and renal DHE oxidation was quantified as a measurement of superoxide
production (magnification × 100; n = 4). (e) Renal pan-macrophages
(F4/80+) and (f) proinflammatory M1 macrophages (CD11c+) were
characterised and quantified by flow cytometry (n = 5). (g–h) Flow
cytometry histogram showing number of CD11c+ positive cells in (g)
wild-type and (h) Adipoq−/− mice, incubated with vehicle (dotted line),
fed an HFD without AICAR (solid line), or fed an HFD with AICAR
(dashed line). Data are presented as mean ± SEM. *p< 0.05, **p < 0.01,
***p< 0.001, ANOVAwith Bonferroni correction; †p< 0.05, ††p < 0.01,
†††p< 0.001, Adipoq−/− vs wild-type mice for respective conditions
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cytokines and promote resolution. Meanwhile, M2b macro-
phages produce IL-12 and IL-10, and are not anti-
inflammatory per se, but rather activate the adaptive B cell
responses and regulate B cell and T cell trafficking [33].
Similar to our findings in mice, compared to vehicle
AICAR promoted a shift towards inflammatory resolution in
human WAT by increasing the percentage of anti-
inflammatory CD206+ macrophages (p<0.05), while reduc-
ing the percentage of proinflammatory CD86+ macrophages
(p<0.05). However, AICAR did not affect human CD11c+ or
CD163+ macrophage expression (Fig. 6a,b), or the CD8+ or
CD4+ T cell populations (Fig. 6c,d) in this 6 h ex vivo exper-
iment. However, AICAR did reduce TNF-α secretion com-
pared to vehicle (p<0.001; Fig. 6e).
Discussion
Obesity is an independent risk factor for numerous
pathologies, including diabetes and liver and kidney disease
[1, 2]. As the prevalence of obesity is increasing worldwide
[3], the search for effective treatments against obesity-related
pathophysiology is ongoing. Here we demonstrate that the
AMPK-activating drug AICAR has therapeutic potential in
this context. AICAR attenuates HFD-induced WAT
inflammation and pathophysiology associated with diabetes,
and liver and kidney disease in an adiponectin-independent
manner. Collectively, these findings support a therapeutic
potential for AICAR in attenuating HFD-induced
pathophysiology (summarised in Fig. 7).
AICAR has previously been reported to increase
metabolism and weight loss [7], even in sedentary mice [8].
Thus, it is not surprising that AICAR-treated HFD-fed mice
gained less weight during the last weeks of the diet regimen,
compared with vehicle-treated HFD-fed control mice. This
effect on weight gain may have mediated some of the
observed beneficial effects of AICAR, but it is unlikely that
this is the sole protective mechanism of this compound since
AICAR-treated HFD-fed mice weighed significantly more
than controls fed an SFD.
Our observation that AICAR attenuatesWAT inflammation
may indicate a key mechanism of action as obesity-induced
adipose inflammation is known to promote systemic






































































































































































































































































































































































































































Fig. 6 AICAR reduces inflammation in adipose explants from obese
individuals. Omental WAT explants from obese individuals (BMI
35–50 kg/m2; n = 4 individuals) were incubated with vehicle or AICAR
(1 mmol/l) for 6 h. (a) Tissue macrophages were characterised as M1
(CD11c+), M1/M2b (CD86+), M2a (CD206+) or M2a/M2c (CD163+)
and (b) quantified. (c) T cells were characterised as CD4+ and CD8+
and (d) quantified. (e) Levels of TNF-α in the supernatant fraction were
determined by ELISA. Data are presented as mean ± SEM. *p < 0.05,
***p< 0.001, Student’s t tests
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macrophages infil trating the obese WAT produce
proinflammatory mediators (TNF-α, IL-1β, IL-6), which are
associated with the development of insulin resistance and the
subsequent release of NEFA, leading to systemic lipotoxicity,
with effects on the liver and kidney [26–28, 35]. AICAR
treatment promoted an M1-to-M2 macrophage phenotype
switch, reducing the percentage of HFD-induced CD11c+
M1 macrophages, while restoring the CD206+ M2 macro-
phage population. Furthermore, AICAR increased WAT
AMPK activity, which has been shown to promote an IL-10-
producing M2 macrophage phenotype [36–38]. In cultured
macrophages, AICAR also promoted an M1-to-M2 pheno-
type switch and increased AMPK activation, suggesting that
the drug may directly manipulate macrophage cell signalling
and phenotypic responses. Additionally, AICAR treatment
reduced HFD-induced CD8+ T cell infiltration, which may
have contributed to the attenuated inflammation since CD8+
T cells facilitate WAT accumulation of inflammatory CD11c+
M1 macrophages [39].
Hepatic steatosis is associated with obesity and diabetes
and enhances susceptibility to liver disease [40, 41]. AICAR
inhibited hepatic steatosis, reducing HFD-induced hepatic
triacylglycerol accumulation in both wild-type and Adipoq−/−
mice. This is in agreement with earlier studies demonstrating
that AICAR reduces diet-induced hepatic triacylglycerol
content in rats [9] and TNF-α-induced intracellular
triacylglycerol accumulation in human hepatic HepG2 cell
lines [11]. AICAR also attenuated HFD-induced hepatic
cholesterol accumulation in Adipoq−/− mice, an interesting
finding since AICAR-induced activation of AMPK inhibits
the hepatic thyroid stimulating hormone (TSH)/sterol regulato-
ry element-binding protein-2 (SREBP-2)/3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMGCR) pathway necessary for
cholesterol biosynthesis [10].
Obesity is an independent risk factor for kidney disease and
25–40% of diabetic individuals develop nephropathy, which
is the primary cause of end-stage renal failure [1, 2, 18]. In this
study, we demonstrate that AICAR treatment attenuates
cardinal features of HFD-induced kidney disease, namely
microalbuminuria, production of reactive oxygen species
and renal inflammation. AICAR did not affect the total
number of renal macrophages in the mouse model used, but
rather shifted their phenotype towards resolution by reducing
the percentage of CD11c+ M1macrophages. Collectively, this
supports previous work from our group and others,
demonstrating that AICAR attenuates both HFD-induced
[12, 13] and diabetes-induced [14, 15] kidney disease.
Importantly, in this study, we now also demonstrate that
AICAR-mediated protection against kidney disease is
independent of adiponectin. This is critical to the clinical
application of AICAR as a potential therapeutic agent
targeting kidney disease. Indeed, it has been debated whether
the use of AICAR could be compromised in patients with
diabetic nephropathy because research indicates that the drug
may increase adiponectin [13]. Although adiponectin is gen-
erally described as a protective adipokine [16] and thought to
protect podocyte function in early onset kidney disease [18,
42–44], the role of adiponectin in the later stages of human
renal failure is unclear [18] with some studies suggesting that
it is harmful [19, 20]. Thus, our finding that AICAR attenuated
HFD-induced kidney disease in an adiponectin-independent
manner may indicate that the drug is a more suitable therapeu-
tic agent for patients with advanced nephropathy.
Importantly, Adipoq−/− mice presented with increased
inflammation, liver vacuolisation and kidney injury compared




































Fig. 7 Schematic illustration of proposed AICAR-mediated effects in
obesity. (a) In obese mice, AICAR treatment attenuates HFD-induced
adipose inflammation, promoting an M1-to-M2 macrophage phenotype
switch by reducing CD8+ T cell infiltration, while increasing p-AMPK
levels. This results in reduced liver and kidney disease and enhanced
glucose tolerance. All of these effects are independent of adiponectin.
(b) AICAR mediates a similar M1-to-M2 macrophage phenotype switch
in adipose explants isolated from obese individuals undergoing bariatric
surgery. MΦ, macrophage
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protective hormone adiponectin. Despite increased injury in the
Adipoq−/− strain, AICAR maintained protection against WAT
inflammation and liver and kidney injury. Thus, we conclude
that this AICAR-mediated protection is independent of
adiponectin. However, although AICAR maintained
renoprotective effects in Adipoq−/− mice, it did not reduce the
increased levels of renal CD11c+ M1macrophages observed in
these mice. Thus, these data indicate that AICAR-mediated
renal protection is not mediated via reduced renal inflammation
per se, but rather we hypothesise that the protection derives
from the reduction of adipose inflammation, as illustrated in
Fig. 7.
To translate our rodent data to human pathophysiology, we
investigated if AICAR could reduce WAT inflammation in
humans. AICAR promoted an M1-to-M2 macrophage
phenotype shift in human WAT explants obtained from obese
individuals. However, we observed important differences in
the specific macrophage phenotypes affected in mice vs
humans. AICAR did not affect M1 CD11c+ macrophage
expression in human WAT, although M1/M2b CD86+ macro-
phage expression was reduced. This may be because AICAR
did not affect the number of human CD8+ T cells, which drive
CD11c+ macrophage infiltration [39]. Importantly, the ex vivo
culture of human tissue with AICARwas limited to 6 h; thus it
is possible that continuous therapeutic administration of the
drug to patients may promote more substantial modulation of
T cell and macrophage phenotypes. AICAR acted in a pro-
resolving manner by increasing the anti-inflammatory
CD206+ macrophage population in human WAT. Since
CD163+ macrophage expression remained unaffected,
AICAR may specifically promote the M2a phenotype.
Finally, AICAR attenuated the level of TNF-α in human
WAT, which is a key functional response in promoting meta-
bolic health.
Collectively, these data support the use of AICAR to
promote metabolic health and to protect against obesity-
induced pathophysiology, such as liver steatosis and kidney
disease. WAT inflammation is a common denominator of
obesity-related pathologies, causing systemic lipotoxicity,
insulin resistance and organ dysfunction. Thus, it is
noteworthy that AICAR reduces WAT inflammation in both
mice and humans. Importantly, AICAR protects against
disease in an adiponectin-independent manner, which may
make AICAR a suitable therapy for individuals with
nephropathy.
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